Cellectis (CLLS) Net Cash Flow (QoQ) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -432.98% |
| Dec 31, 2025 | 185.75% |
| Sep 30, 2025 | 86.22% |
| Jun 30, 2025 | -295.24% |
| Mar 31, 2025 | -23.54% |
| Dec 31, 2024 | -212.18% |
| Sep 30, 2024 | -49.36% |
| Jun 30, 2024 | 280.11% |
| Mar 31, 2024 | -118.87% |
| Dec 31, 2023 | 554.39% |
| Sep 30, 2023 | -1,478.49% |
| Jun 30, 2023 | 88.17% |
| Sep 30, 2022 | -37.90% |
| Jun 30, 2022 | -667.39% |
| Sep 30, 2021 | -190.62% |
| Jun 30, 2021 | 3,763.78% |
| Mar 31, 2021 | 90.12% |
| Dec 31, 2020 | -64.30% |
| Sep 30, 2020 | 75.37% |
| Jun 30, 2020 | 43.76% |
| Mar 31, 2020 | -350.68% |
| Dec 31, 2019 | 77.94% |
| Sep 30, 2019 | -96.92% |
| Jun 30, 2019 | 11.04% |
| Mar 31, 2019 | -25.06% |
| Dec 31, 2018 | -526.28% |
| Sep 30, 2018 | -97.78% |
| Jun 30, 2018 | 1,498.11% |
| Mar 31, 2018 | -87.81% |
| Dec 31, 2017 | -130.42% |
| Sep 30, 2017 | 201.11% |
| Jun 30, 2017 | -56.70% |
| Mar 31, 2017 | -138.27% |
| Dec 31, 2016 | 647.82% |
| Sep 30, 2016 | 141.07% |
| Jun 30, 2016 | 87.07% |
| Mar 31, 2016 | -511.44% |
| Dec 31, 2015 | 726.52% |
| Sep 30, 2015 | -102.47% |
| Jun 30, 2015 | 4,561.35% |